Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 14 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-0.99 Insider Own17.53% Shs Outstand132.23M Perf Week-12.66%
Market Cap998.88M Forward P/E164.70 EPS next Y0.05 Insider Trans-29.92% Shs Float109.55M Perf Month-32.86%
Income-131.04M PEG- EPS next Q0.00 Inst Own90.44% Short Float5.60% Perf Quarter-2.34%
Sales274.10M P/S3.64 EPS this Y-151.11% Inst Trans-0.47% Short Ratio2.82 Perf Half Y26.81%
Book/sh3.10 P/B2.43 EPS next Y397.79% ROA-6.97% Short Interest6.13M Perf Year-46.09%
Cash/sh4.23 P/C1.78 EPS next 5Y- ROE-28.11% 52W Range4.52 - 14.88 Perf YTD14.81%
Dividend Est.- P/FCF- EPS past 5Y-37.53% ROI-13.65% 52W High-49.46% Beta0.04
Dividend TTM- Quick Ratio10.47 Sales past 5Y47.72% Gross Margin40.80% 52W Low66.37% ATR (14)0.45
Dividend Ex-Date- Current Ratio11.32 EPS Y/Y TTM-185.12% Oper. Margin-13.44% RSI (14)27.50 Volatility4.16% 4.82%
Employees650 Debt/Eq1.37 Sales Y/Y TTM-61.81% Profit Margin-47.81% Recom1.58 Target Price10.85
Option/ShortYes / Yes LT Debt/Eq1.34 EPS Q/Q-18160.00% Payout- Rel Volume0.71 Prev Close7.76
Sales Surprise6.01% EPS Surprise23.37% Sales Q/Q-18.79% EarningsMay 08 AMC Avg Volume2.18M Price7.52
SMA20-20.83% SMA50-15.92% SMA200-1.45% Trades Volume1,556,236 Change-3.09%
Date Action Analyst Rating Change Price Target Change
Apr-10-24Initiated Craig Hallum Buy $15
Dec-12-23Upgrade BofA Securities Neutral → Buy $10 → $8
Aug-08-23Downgrade KeyBanc Capital Markets Overweight → Sector Weight
May-23-23Downgrade Credit Suisse Outperform → Neutral $18 → $14
May-09-23Downgrade Goldman Buy → Neutral
Jan-05-23Downgrade UBS Buy → Neutral $20 → $16
Dec-14-22Initiated Deutsche Bank Buy $25
Dec-07-22Initiated RBC Capital Mkts Outperform $22
Nov-03-22Downgrade BofA Securities Buy → Neutral $32 → $17
Aug-25-22Initiated Credit Suisse Outperform $34
Jun-12-24 02:38AM
May-17-24 11:52AM
May-13-24 08:00AM
May-09-24 04:18PM
10:53AM Loading…
May-08-24 08:57PM
Apr-30-24 07:31AM
Apr-18-24 07:36AM
Apr-10-24 04:05PM
Mar-28-24 04:00PM
07:48AM Loading…
Mar-19-24 07:48AM
Mar-12-24 04:15PM
Feb-23-24 12:15PM
Feb-22-24 08:30PM
Feb-21-24 08:00AM
Feb-13-24 08:30AM
Feb-11-24 05:00PM
Feb-07-24 06:46AM
Jan-29-24 08:00AM
Dec-18-23 05:27AM
Nov-24-23 08:39AM
Nov-09-23 08:15AM
04:02PM Loading…
Nov-08-23 04:02PM
Nov-07-23 04:49PM
Nov-02-23 06:47AM
Oct-20-23 12:08PM
Oct-17-23 08:15AM
Sep-29-23 12:43PM
Sep-25-23 08:49AM
Sep-19-23 09:31AM
Sep-05-23 04:15PM
Aug-23-23 08:15AM
Aug-22-23 08:14AM
Aug-09-23 04:15PM
Aug-08-23 06:20AM
Aug-07-23 04:05PM
Jul-27-23 04:05PM
Jul-24-23 04:05PM
Jul-20-23 04:05PM
Jul-18-23 08:37AM
Jul-16-23 08:51AM
Jun-06-23 08:00AM
May-24-23 08:10AM
May-09-23 12:49PM
May-08-23 05:35PM
Apr-17-23 04:15PM
Mar-28-23 05:00PM
Mar-20-23 06:50AM
Mar-13-23 08:45AM
Mar-09-23 06:40AM
Mar-08-23 08:00AM
Mar-04-23 08:19AM
Mar-02-23 08:45AM
Feb-27-23 05:35AM
Feb-23-23 01:00AM
Feb-22-23 05:55PM
Feb-16-23 10:01AM
Feb-15-23 10:00AM
Feb-14-23 04:33PM
Feb-07-23 10:15AM
Feb-06-23 07:34AM
Feb-01-23 08:00AM
Jan-27-23 09:37AM
Jan-16-23 08:30AM
Dec-12-22 09:53AM
Dec-01-22 04:01PM
Nov-28-22 08:30AM
Nov-16-22 05:05PM
Nov-09-22 07:16AM
Nov-07-22 04:10PM
Nov-06-22 07:30AM
Nov-03-22 04:05PM
Nov-02-22 06:15PM
Oct-29-22 08:45AM
Oct-24-22 10:39AM
Oct-19-22 08:10AM
Oct-18-22 04:15PM
Oct-13-22 08:32PM
Oct-08-22 08:28AM
Oct-06-22 11:28AM
Oct-03-22 04:05PM
Maravai Lifesciences Holdings, Inc. is a life sciences company. It is engaged in providing products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. The firm operates through the following segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment focuses on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers' research, therapeutic and vaccine programs. The Biologics Safety Testing segment focuses on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. The company was founded by Eric Tardif and Carl W. Hull in March 2014 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GTCR INVESTMENT XI LLCDirectorMay 28 '24Sale9.819,940,97497,570,66020,150,005May 30 05:39 PM